S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

OCUL Ocular Therapeutix Inc

9.92

0.00 (0.00%)

Pre Market

Last Updated: 04:04:07

Delayed by 15 minutes

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Ocular Therapeutix Charts.

Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Ocular Therapeutix Charts.

Ocular Therapeutix Inc News

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (13 hours ago) • Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Thursday 14 November 2024 (22 hours ago) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Thursday 14 November 2024 (24 hours ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 14 November 2024 (24 hours ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 14 November 2024 (1 day ago) • Edgar (US Regulatory)

Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights
Thursday 14 November 2024 (1 day ago) • GlobeNewswire Inc.

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV
Wednesday 13 November 2024 (2 days ago) • GlobeNewswire Inc.

Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer
Tuesday 12 November 2024 (3 days ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 8 November 2024 (7 days ago) • Edgar (US Regulatory)

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
Wednesday 6 November 2024 (1 week ago) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Wednesday 16 October 2024 (4 weeks ago) • Edgar (US Regulatory)

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD
Tuesday 15 October 2024 (1 month ago) • GlobeNewswire Inc.

More Ocular Therapeutix Inc News Articles

NLBNPIT1ZYV4 20991231 91...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions